|
ナカミゾ ムネナガ
中溝 宗永 所属 医学部 医学科（東京女子医科大学病院） 職種 特任教授 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Optimization of therapeutic strategy for p16-positive oropharyngeal squamous cell carcinoma: Multi-institutional observational study based on the national head and neck cancer registry of Japan. |
| 掲載誌名 | 正式名：Cancer 略 称：Cancer ISSNコード：10970142/0008543X |
| 掲載区分 | 国外 |
| 巻・号・頁 | pp.10.1002/cncr.33062 |
| 著者・共著者 | Saito Yuki, Hayashi Ryuichi, Iida Yoshiyuki, Mizumachi Takatsugu, Fujii Takashi, Matsumoto Fumihiko, Beppu Takeshi, Yoshida Masafumi, Shinomiya Hirotaka, Kamiyama Ryosuke, Kitano Mutsukazu, Yokoshima Kazuhiko, Fujimoto Yasushi, Hama Takanori, Yamashita Taku, Okami Kenji, Miura Kouki, Fujisawa Takuo, Sano Daisuke, Kato Hisayuki, Minami Shujiro, Sugasawa Masashi, Masuda Muneyuki, Ota Ichiro, Iwae Shigemichi, Kawata Ryo, Monden Nobuya, Imai Takayuki, Asakage Takahiro, Okada Masafumi, Yoshikawa Takanori, Tanioka Kensuke, Kitayama Megumi, Doi Mariko, Fujii Satoshi, Fujii Masato, Oridate Nobuhiko, Nakamizo Munenaga, Yoshimoto Seiichi, Homma Akihiro, Nibu Ken-Ichi, Yane Katsunari |
| 発行年月 | 2020/07 |
| 概要 | BACKGROUND:Although the American Joint Committee on Cancer TNM classification has been amended to include human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) as an independent entity, to the authors' knowledge the optimized de-escalating treatment modality has not been established to date.METHODS:The authors conducted a retrospective, nationwide, observational study in patients with HPV-related OPSCC who were treated from 2011 to 2014 in Japan to determine the best treatment modality.RESULTS:A total of 688 patients who were newly diagnosed with HPV-related OPSCC who were treated with curative intent at 35 institutions and had coherent clinical information and follow-up data available were included in the current study. In patients with T1-T2N0 disease (79 patients), both the 3-year recurrence-free survival and overall survival (OS) rates were 100% in the group treated with radiotherapy (RT) as well as the group receiving concurrent chemoradiotherapy (CCRT). The 3-year OS rates were 94.4% (for patients with T1N0 disease) and 92.9% (for patients with T2N0 disease) among the patients treated with upfront surgery. In patients with stage I to stage II HPV-related OPSCC, the 5-year recurrence-free survival and OS rates were 91.4% and 92%, respectively, in the patients treated with CCRT with relatively high-dose cisplatin (≥160 mg/m2 ; 114 patients) and 74.3% and 69.5%, respectively, in the patients treated with low-dose cisplatin (<160 mg/m2 ; 17 patients).CONCLUSIONS:Despite it being a retrospective observational trial with a lack of information regarding toxicity and morbidity, the results of the current study demonstrated that patients with T1-T2N0 HPV-related OPSCC could be treated with RT alone because of the equivalent outcomes of RT and CCRT, and patients with stage I to stage II HPV-related OPSCC other than those with T1-T2N0 disease could be treated with CCRT with cisplatin at a dose of ≥160 mg/m2 . |
| DOI | 10.1002/cncr.33062 |
| PMID | 32648953 |